Highlights from MAP2024
The Molecular Analysis for Precision Oncology Congress 2024 (MAP2024) occurred from October 16 to 18, 2024, in London, UK.
This event concentrated on both current and emerging strategies in precision oncology, addressing successes and challenges while suggesting actionable solutions for clinical research and practice.
The congress is a collaborative effort among three key organizations: Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO), and Unicancer. These institutions are dedicated to enhancing cancer care globally through education and research initiatives.
Scientific Co-Chairs:
- Lisa Derosa – Villejuif, France (Unicancer)
- Mariam Jamal-Hanjani – London, UK (CRUK)
- Joaquin Mateo – Barcelona, Spain (ESMO)
Here are some highlights from the event:
ESMO:
“MAP2024: Advances in spatial transcriptomics could provide novel opportunities for early detection, metastasis prediction and identification of actionable targets.”
“MAP2024 Day 2 Morning Session chaired by Myriam Chalabi and Sabine Tejpar.
Learning from dMMR/MSI CRC. Immunotherapy/cellular therapies for subgroups of MSS remain the challenge – follow the science but not down the rabbit hole?
ESMO, Mariam Jamal-Hanjani and faculty co chairs.”
“Understanding mutations through molecular profiling at MAP2024.”
“You can always make it about the androgen receptor (internal bias very much disclosed). Thanks, ESMO for the invite. Congratulations to Derosa Lisa, Mariam Jamal-Hanjani, and Joaquin Mateo for a fantastic MAP2024. Many many wonderful people who will make a difference to our patients.”
ESMO:
“Three studies at MAP2024 show that analysing CTCs, exo-miRNA, and cfRNA from plasma samples can improve cancer progression prediction and early detection, expanding the potential of Liquid Biopsy beyond ctDNA analysis.”
“Thrilled to present our study on epigenomic and genomic convergence in tumor evolution on the TRACERx cohort with Nnennaya Kanu and Charles Swanton: DNA methylation co-operates with genomic alterations during NSCLC evolution. Huge thanks to MAP2024 for awarding us best poster!”
“Super days in London with old and new friends at Molecular Analysis for Precision Oncology (MAP) 2024!!”
“Happening now MAP2024, Artificial Intelligence Proferred Paper Session – with Santi Demajo Meseguer, Barcelona Biomedical Genomics Lab, Carlos Macarro, Vall d’Hebron Institute of Oncology (VHIO), and B Ocasio.”
ESMO:
“New insights into endocrine therapy resistance mechanisms in Breast Cancer were presented at MAP2024, unveiling a potential role of ESR1 gene fusions and providing important information for guiding treatment.”
For more posts like this, visit oncodaily.com.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023